Aller au contenu principal
Accès ouvert déclaré 2025 article

Transdermal Allergen-Specific Immunotherapy Using a Biodegradable Microneedle Array Patch in a Murine Model of Peanut Anaphylaxis

1Citations signalées, ce qui n’est pas une note de qualité
4Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : de, kr. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

PURPOSE: Peanut anaphylaxis is a widespread challenge, particularly in children. We aimed to confirm the therapeutic effects of transdermal immunotherapy (TDIT) in a murine model of peanut anaphylaxis. METHODS: We developed a biodegradable microneedle array patch (MAP) by incorporating peanut extract (PE) with hyaluronic acid. The allergenicity of the PE in MAP was assayed by enzyme-linked immunosorbent assay inhibition. The peanut anaphylaxis model was made with BALB/c or C3H/Hej mouse strains. We measured anaphylaxis clinical scores, as well as the levels of mouse mast cell protease-1 (MCPT-1), PE-specific immunoglobulin E (sIgE), specific immunoglobulin G (sIgG)1, and sIgG2a in serum. T cell populations in the spleen and jejunum were examined using immunohistochemical stains with confocal microscopy. Histological analysis of the jejunum was performed. The production of T helper cell type 2 (Th2) and regulatory T cell (Treg) cytokines by stimulated splenocytes were also measured. RESULTS: The inhibitory capacity of the PE in MAP for PE sIgE was comparable to that of native PE. TDIT with 10 μg of PE-MAP recovered anaphylaxis score, sIgE, and the MCPT-1 levels, and enhanced sIgG1 and sIgG4 in serum. TDIT also reduced the recruitment of Th2 cells while increasing Treg and Th1 cells in both the spleen and jejunum. However, the efficacy of applying 10 μg of PE-MAP TDIT twice a week was more pronounced than applying once a week. Additionally, TDIT led to reduced production of Th2 cytokines (interleukin [IL]-4, IL-5, IL-13) and increased production of transforming growth factor-β by stimulated splenocytes. TDIT attenuated inflammation, mast cell infiltration, and villous damage in the jejunum. CONCLUSIONS: PE-MAP TDIT demonstrated therapeutic effects in peanut anaphylaxis, suggesting its potential for developing a novel TDIT for patients with peanut anaphylaxis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Transdermal Allergen-Specific Immunotherapy Using a Biodegradable Microneedle Array Patch in a Murine Model of Peanut Anaphylaxis
Date Crossref
01/01/2025
Éditeur
XMLink
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Food Allergy and Anaphylaxis ResearchAdvancements in Transdermal Drug DeliveryAllergic Rhinitis and Sensitization

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.